+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Anxiety Disorders and Depression Treatment Market to Exhibit 1.25% CAGR in View of Unimpressive Drug Pipeline

Posted on Jan 08, 2016

With anxiety disorders and depression becoming a substantial public health burden, efforts are increasingly afoot to reduce their impact. A large part of this endeavor entails the use of anxiolytics and antidepressants, which will augur well for the global anxiety disorders and depression treatment market. According to a new report published by Transparency Market Research, the global anxiety disorders and depression treatment market will log a 1.25% CAGR to go from its 2013 valuation of US$22.5 bn down to US$18.2 bn by 2020. These findings are discussed in detail in TMR’s report, titled ‘Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.

Browse the full Anxiety Disorders and Depression Treatment Market [Drug Classes: SSRIs, SNRIs, Benzodiazepines, Beta Blockers, TCAs, TeCAs, Atypical Antipsychotics, Anticonvulsants and MAOIs] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html

 

The report, however, notes that the market for anxiety disorders and depression treatment will be restricted to a great degree by leading drugs in the market on the brink of facing a patent expiration. This is compounded by a relatively dry pipeline of anxiety disorder and depression treatment drugs. The report further notes that drug-resistant mental disorders could pose an impediment to the growth of the global anxiety disorders and depression treatment market.

Data released by the World Health Organization in October 2015 states that over 350 million people across all ages suffer from depression. Given the possibility of acute depression leading to suicide, healthcare agencies are taking measures to tackle the burden using effective drugs and therapies. This will be a high-impact driver for the global anxiety disorders and depression treatment market, says TMR.

TMR analysts recommend players in the market to focus on enhancing and fine-tuning distribution networks in emerging economies and developing herbal therapies to treat depression and anxiety disorders. Countries such as Brazil, China, India, Singapore, Dubai, Mexico, and South Africa have remunerative potential for generic pharmaceuticals, the report states.

For an in-depth analysis, the report segments the global anxiety disorders and depression treatment market on the basis of drug class, pipeline analysis, and geography. Based on drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), atypical antipsychotics, tetracyclic antidepressants (TeCAs), beta-blockers, benzodiazepines, and monoamine oxidase inhibitors (MAOIs). Although SNRIs comprised the leading segment in the market as of 2013 with a share of over 30%, their hold on the market is expected to loosen in the coming years.

Likewise, on the basis of pipeline, the market is segmented into Brexpiprazole (OPC-34712), ALKS-5461, and Brintellix (Vortioxetine - Lu AA21004).

The report studies the following regional markets for anxiety disorders and depression treatment: North America, Asia Pacific, Europe, and Rest of the World. Of these, North America was the leading regional market for anxiety disorders and depression treatment given the high prevalence of depression and anxiety disorders here. However, the report describes this market as nearing saturation – a trend that will only change with the launch of novel drugs for newer symptoms. The growth of the anxiety disorders and depression treatment market in Asia Pacific will be moderate, driven mostly by countries such as Australia, China, and Japan.

The global anxiety disorders and depression treatment market is segmented as follows:

  • Anxiety Disorders and Depression Treatment Market, by Drug Class
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • Atypical Antipsychotics
    • Tricyclic Antidepressants (TCAs)
    • Tetracyclic Antidepressants (TeCAs)
    • Monoamine Oxidase inhibitors (MAOIs)
    • Benzodiazepines
    • Beta-Blockers
    • Anticonvulsants
  • Anxiety Disorders and Depression Treatment Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

Browse : Our new press releases http://www.transparencymarketresearch.com/pressrelease/global-anxiety-disorders-depression-treatments.htm

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact                    

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Back To Top